Sandbox: sadaf: Difference between revisions

Jump to navigation Jump to search
Line 68: Line 68:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
|-
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! rowspan="14" |Hematology
! align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia
! rowspan="4" align="center" style="background:#DCDCDC;" + |Bone marrow disorders
!Myelodysplastic syndromes
!
!
|
|
|
|
|
Line 95: Line 95:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!Aplastic anemia
!
!
! align="center" style="background:#DCDCDC;" + |Chronic liver disease
!
|
|
|
|
|
Line 132: Line 130:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Acute leukemia
!
!
! align="center" style="background:#DCDCDC;" + |portal hypertension
!
|
|
|
|
|
Line 159: Line 155:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!Paroxysmal nocturnal hemoglobinuria (PNH)
!
!
! align="center" style="background:#DCDCDC;" + |Hypersplenism
!
|
|
|
|
|
Line 191: Line 185:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |Diagnosis of exclusion
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
! rowspan="2" |'''Thrombotic microangiopathy (TMA)'''
!Thrombotic thrombocytopenic purpura (TTP)
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! align="center" style="background:#DCDCDC;" + |Immune thrombocytopenia
!
!
|Antibody-mediated platelet destruction
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |Moderate to severe
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |Diagnosis of exclusion
| align="left" style="background:#F5F5F5;" + |
|-
|-
!Hemolytic uremic syndrome (HUS)
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders
! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders
! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders
! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders
Line 260: Line 282:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!
! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome
! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome
|
|
Line 291: Line 312:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!
! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome
! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome
|
|
Line 322: Line 342:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!
! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome
! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome
|
|
Line 353: Line 372:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!
! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome
! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome
|
|
Line 384: Line 402:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!
! align="center" style="background:#DCDCDC;" + |Alport syndrome
! align="center" style="background:#DCDCDC;" + |Alport syndrome
|
|
Line 415: Line 432:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!
! align="center" style="background:#DCDCDC;" + |Von Willebrand disease
! align="center" style="background:#DCDCDC;" + |Von Willebrand disease
|
|
Line 446: Line 462:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!'''Nutrient deficiencies'''
!Folate, vitamin B12, copper
|an autoimmune mechanism
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
! rowspan="4" |'''Rheumatologic/autoimmune disorders'''
!Immune thrombocytopenia
!
|Antibody-mediated platelet destruction
|
|
|
|
Line 454: Line 502:
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |Moderate to severe
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 478: Line 525:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Systemic lupus erythematosus (SLE)
!
!
!
!
!
|
|
|
|
|
Line 510: Line 556:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Antiphospholipid syndrome (APS)
!
!autoantibody-mediated syndrome
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
!Felty's syndrome
!
!splenomegaly
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
! rowspan="2" |
!
!
!
!
Line 542: Line 650:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!
!
!
!
!
Line 792: Line 899:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="6" |Drug-induced
! rowspan="5" |Drug-induced
! align="center" style="background:#DCDCDC;" + |Drug-induced immune thrombocytopenia
! align="center" style="background:#DCDCDC;" + |Drug-induced immune thrombocytopenia
!
!
Line 958: Line 1,065:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |'''Alcohol'''
! rowspan="2" |GI
!
!Chronic liver disease
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
!
!'''Malignancy'''
!
!
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
!
!'''Nutrient deficiencies'''
!folate, vitamin B12, copper
|an autoimmune mechanism
|
|
|
|
Line 1,053: Line 1,097:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Portal hypertension
!
!
! rowspan="3" |'''Thrombotic microangiopathy (TMA)'''
!Thrombotic thrombocytopenic purpura (TTP)
|
|
|
|
Line 1,085: Line 1,128:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="3" |Vascular
!Giant capillary hemangioma
!
!
!Hemolytic uremic syndrome (HUS)
!platelet destruction
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
!
!Drug-induced TMA (DITMA)
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
! rowspan="4" |'''Bone marrow disorders'''
!Myelodysplastic syndromes
!
!
!
!
!
!
Line 1,179: Line 1,160:
!
!
|-
|-
!Aplastic anemia
!Aortic aneurysm
!
!
!
!platelet destruction
!
!
!
!
Line 1,210: Line 1,191:
!
!
|-
|-
!Acute leukemia
!Cardiopulmonary bypass
!
!
!
!platelet destruction
!
!
!
!
Line 1,241: Line 1,222:
!
!
|-
|-
!Paroxysmal nocturnal hemoglobinuria (PNH)
! rowspan="3" |Other
!Alcohol
!
!
!
!
Line 1,272: Line 1,254:
!
!
|-
|-
!'''Rheumatologic/autoimmune disorders'''
!Post-transfusion purpura
!Systemic lupus erythematosus (SLE)
!
!
!
!immune-mediated platelet destruction
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
!
!Antiphospholipid syndrome (APS)
!
!autoantibody-mediated syndrome
!
!
!
!
Line 1,336: Line 1,285:
!
!
|-
|-
!Gestational thrombocytopenia
!
!
!Felty's syndrome
!
!splenomegaly
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
! rowspan="3" |vascular
!giant capillary hemangioma,
!
!
!platelet destruction
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
!large aortic aneurysms,
!
!platelet destruction
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
!cardiopulmonary bypass
!
!platelet destruction
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
!
!Post-transfusion purpura
!
!immune-mediated platelet destruction
!
!
!
!

Revision as of 20:54, 14 August 2018

Thrombocytopenia Differential Diagnosis

Differentiating the diseases that can cause thrombocytopenia:

Category Condition Mechanism Age range Clinical manifestations Para−clinical findings Gold standard Associated findings
Symptoms Signs
Lab Findings Imaging
Severity Fever Bleeding BP Splenomegaly CBC PBS Bone marrow exam
Myelosuppression Platelet destruction in bloodstream Platelet destruction in spleen/liver History Plt HB WBC PT PTT BT
Hematology Bone marrow disorders Myelodysplastic syndromes
Aplastic anemia
Acute leukemia
Paroxysmal nocturnal hemoglobinuria (PNH) Diagnosis of exclusion
Thrombotic microangiopathy (TMA) Thrombotic thrombocytopenic purpura (TTP)
Hemolytic uremic syndrome (HUS)
Congenital platelet disorders MYH-9 related disorders
Bernard-Soulier syndrome
Gray platelet syndrome
Wiskott-Aldrich syndrome
Thrombocytopenia with absent radius (TAR) syndrome
Alport syndrome
Von Willebrand disease
Nutrient deficiencies Folate, vitamin B12, copper an autoimmune mechanism
Rheumatologic/autoimmune disorders Immune thrombocytopenia Antibody-mediated platelet destruction Moderate to severe -
Systemic lupus erythematosus (SLE)
Antiphospholipid syndrome (APS) autoantibody-mediated syndrome
Felty's syndrome splenomegaly
Infection-induced Viral infections rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus
HIV
  • Direct toxicity to megakaryocytes
  • An ITP-like condition called primary HIV-associated thrombocytopenia (PHAT)
  • Secondary opportunistic infections
Bacterial infections Sepsis Direct bone marrow suppression +
Helicobacter pylori Immune thrombocytopenia
Leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections
Intracellular parasites Malaria
Babesiosis
Drug-induced Drug-induced immune thrombocytopenia
  • Antibiotics
    • Sulfonamides
    • Ampicillin
    • Piperacillin
    • Vancomycin
    • Rifampin
  • Older antiepileptic agents
    • carbamazepine
    • Phenytoin
  • Quinine
Occurrence of drug-dependent, platelet-reactive antibodies
Heparin-induced thrombocytopenia
Cytotoxic chemotherapy
Radiation therapy Predictable, dose-dependent myelosuppression
OTC agents Quinine-containing beverages
GI Chronic liver disease Mild
Portal hypertension
Vascular Giant capillary hemangioma platelet destruction
Aortic aneurysm platelet destruction
Cardiopulmonary bypass platelet destruction
Other Alcohol
Post-transfusion purpura immune-mediated platelet destruction
Gestational thrombocytopenia